| Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526) |
|---|
| 03/06/2007 | US7186881 Monitoring effectiveness of anti-alzheimer agents via measurement of adjustments in synaptophysin gene expression; tissue engineering |
| 03/06/2007 | US7186879 Screening systems and methods for identifying modulators of xenobiotic metabolism |
| 03/06/2007 | US7186821 Expression vector comprising nucleotide sequences coding transport protein and infection resistant genomes for use in enhancing disease resistance and vascular transport in plants |
| 03/06/2007 | US7186819 Glutamate receptor and utilization thereof |
| 03/06/2007 | US7186818 DNA encoding soluble variants of human OX2 receptors |
| 03/06/2007 | US7186816 Photolyase nucleic acids |
| 03/06/2007 | US7186812 Comprises peptides associated with purinergic receptors for treating neurodegenerative, psychological and nervous system disorders; mimetics |
| 03/06/2007 | US7186811 Preparing a bone morphogenetic protein complex by extraction with guanidine hydrochloride, concentration with ultrafiltration, dialysis, high pressure liquid chromatography gel filtration into three fractions, and drying and sterilization of the first fraction; storage stability |
| 03/06/2007 | US7186810 Modified peptides as therapeutic agents |
| 03/06/2007 | US7186805 Fusion proteins; for inhibition of cognate receptor |
| 03/06/2007 | US7186804 IL-2 fusion proteins with modulated selectivity |
| 03/06/2007 | US7186803 Human vanilloid receptor VR3 protein |
| 03/06/2007 | US7186802 Membrane proteins; for treatment of inflammation, asthma, allergy, metastasis of cancer cells, ion transport disorders such as magnesium defects in the kidney, and inflammatory bowel disease |
| 03/06/2007 | US7186801 Polypeptide encoded by a nucleic acid underexpressed in stomach tumor and lung tumor |
| 03/06/2007 | US7186800 Fc domains of immunoglobulins; fas genes/proteins; drug screening |
| 03/06/2007 | US7186798 Derived from ghrelin polypeptide, labelled with fluorochrome and cysteine; drug screening; high throughput assay |
| 03/06/2007 | US7186797 Stability in blood ; complexing using compound containing phosphate group |
| 03/06/2007 | US7186795 Lactoferricin gene and transformant expressing lactoferricin |
| 03/06/2007 | US7186699 Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
| 03/06/2007 | US7186698 Focusing ultrasonic frequency; magnetic resonance imaging |
| 03/06/2007 | US7186697 Delivery system contains a fusion protein having a target moiety and a nucleic acid binding moiety, and a nucleic acid sequence bound to the nucleic acid binding moiety of the fusion protein. The target moiety can be an antibody or a |
| 03/06/2007 | US7186694 Modulation body weights; dietetics; eating disorders |
| 03/06/2007 | US7186693 Metalloproteinase inhibitors for wound healing |
| 03/06/2007 | US7186692 adminstering peptide YY, Neuropeptide Y, or Pancreatic polypeptide with solubilizing agent (cyclodextran), chelating agent (ethylenediamine tetraacetic acid), and polyol such as sucrose |
| 03/06/2007 | US7186691 Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity |
| 03/06/2007 | US7186689 Aftertreatment hip replacement; prevention forming extra bones |
| 03/06/2007 | US7186688 Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2 |
| 03/06/2007 | US7186685 Mixture of carotenoids, preferably lutein, and gelatin-glycine for improving hydration, elasticity and lipid content of the skin and for protecting skin and ocular tissues from hazardous radiations |
| 03/06/2007 | US7186682 Modulator of TNF/NGF superfamily receptors and soluble oligomeric TNF/NGF superfamily receptors |
| 03/06/2007 | US7186563 Methods and compositions for regulating plant stress tolerance |
| 03/06/2007 | US7186562 Isolated nucleic acids encoding xanthomonan polypeptides and uses thereof |
| 03/06/2007 | US7186561 Plant polynucleotides encoding novel Na+/H+ antiporters |
| 03/06/2007 | US7186552 Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
| 03/06/2007 | US7186545 Probiotic strains from Lactobacillus salivarius and antimicrobial agents obtained therefrom |
| 03/06/2007 | US7186540 Thermostable glutaminase and thermostable glutaminase gene |
| 03/06/2007 | US7186536 A genetic engineered protein encoded by a DNA sequence or a hybrids, culturng the transformant cells, drug screening, for developing cell growth inhibitors or antitumor agents |
| 03/06/2007 | US7186529 Genetic engineered human cell contains an endogenous EPO (erythropoietin) gene in linkage with a heterologous viral promoters, SV40 or Cytomegalo virus |
| 03/06/2007 | US7186528 Method for preparing a physiologically active IL-18 polypeptide |
| 03/06/2007 | US7186527 Goodpasture antigen binding protein |
| 03/06/2007 | US7186526 Useful in effecting accelerated healing of wounds, bone fractures, burn tissue, damaged myocardial tissue, degenerated neurological tissue, or other trauma |
| 03/06/2007 | US7186524 Preparing transgenic vectors capable of transformation, propagation and expression of cell surface ligand binding activity in host cells; drug screening |
| 03/06/2007 | US7186521 Determining the effect of a substance on sequestration, uptake, and accumulation of amyloid in brain cells |
| 03/06/2007 | US7186517 Compositions and methods for monitoring breast cancer treatment |
| 03/06/2007 | US7186514 Nucleotide sequences coding tumor marker protein for use in diagnosis and/or prognosis of cell proliferative disorders |
| 03/06/2007 | US7186513 Methods for monitoring multiple gene expression |
| 03/06/2007 | US7186412 Fusion proteins of Mycobacterium tuberculosis |
| 03/06/2007 | US7186408 Immunomodulators; for treatment of inflammation |
| 03/06/2007 | US7186407 Including claudication and critical limb ischemia, by administering fibroblast growth factor (FGF) in two doses, a single dose administered into each leg of the patient within one hour |
| 03/06/2007 | CA2518298A1 Biodegradable polymers, their preparation and their use for the manufacture of bandages |
| 03/06/2007 | CA2320488C Strategically modified hepatitis b core proteins and their derivatives |
| 03/06/2007 | CA2141670C Peptides, analogues and mixtures thereof for detecting and eliciting antibodies to the e1 and e2 protein of rubella virus |
| 03/01/2007 | WO2007025248A2 Aggrecanase structure |
| 03/01/2007 | WO2007025219A2 Nogo receptor polypeptides and polypeptide fragments and uses thereof |
| 03/01/2007 | WO2007024668A2 Targeting of herpes simplex virus to specific receptors |
| 03/01/2007 | WO2007024290A2 Nanoscale neuromodulating platform for retina neuron activation apparatus and method |
| 03/01/2007 | WO2007024029A1 Antiviral agent and viral replication inhibitor |
| 03/01/2007 | WO2007023816A1 Method for preparation of reduced keratin, reduced cuticle protein or mixture thereof |
| 03/01/2007 | WO2007023811A1 Process for producing heavy atom derivative using vaporized iodine, method for collecting phase information, and method for determining three-dimensional structure of protein crystal |
| 03/01/2007 | WO2007023782A1 Neutralizing antibody directed against killer toxin-like protein, and use thereof |
| 03/01/2007 | WO2007023686A1 Novel apoptosis inducing factor and method of inducing apoptosis using the same |
| 03/01/2007 | WO2007023628A1 Secretory antigen 1 protein of babesia gibsoni, dna encoding the same and use thereof |
| 03/01/2007 | WO2007023316A2 Assay for trypanosome infection |
| 03/01/2007 | WO2007023178A1 Prion inactivation |
| 03/01/2007 | WO2007023163A1 Polypeptides having antimicrobial activity and polynucleotides encoding same |
| 03/01/2007 | WO2007022799A1 Process for the preparation of glycosylated interferon beta |
| 03/01/2007 | WO2007022774A1 THERAPEUTICALLY ACTIVE α-MSH ANALOGUES |
| 03/01/2007 | WO2007022768A2 Method and means for enrichment removal and detection of listeria |
| 03/01/2007 | WO2007022623A1 Regulation of heterologous recombinant protein expression in methylotrophic and methanotrophic bacteria |
| 03/01/2007 | WO2007008071A3 Method for detecting peptides comprising a cross-beta structure |
| 03/01/2007 | WO2007005389A9 F11 receptor (f11r) antagonists as therapeutic agents |
| 03/01/2007 | WO2006136392A3 Novel genes and proteins of brachyspira pilosicoli and use of same for diagnosis and therapy |
| 03/01/2007 | WO2006128460A3 Pegylated g-csf polypeptides and methods of producing same |
| 03/01/2007 | WO2006119965A3 Growth factor mutants with altered biological attributes |
| 03/01/2007 | WO2006119767A3 Neuritogenic peptides |
| 03/01/2007 | WO2006119497A3 Acetylycholine gated ion channel chaperons and methods of using the same |
| 03/01/2007 | WO2006117241A3 Polypeptide, vaccine and use thereof |
| 03/01/2007 | WO2006116292A3 Methods for reducing the immunogenicity of cytokines and removal of cell surface markers |
| 03/01/2007 | WO2006116269A3 Antibodies to myostatin |
| 03/01/2007 | WO2006111946A3 Toll-like receptor 14 (tlr14 ) and use thereof |
| 03/01/2007 | WO2006110589A8 Gammaretrovirus associated with cancer |
| 03/01/2007 | WO2006091727A3 Single branch heparin-binding growth factor analogs |
| 03/01/2007 | WO2006084466A3 Surface-located streptococcus pneumoniae polypeptides |
| 03/01/2007 | WO2006081573A3 Homogeneous preparations of il-31 |
| 03/01/2007 | WO2006077146A3 Method for producing albumin conjugates containing gyrase inhibitors |
| 03/01/2007 | WO2006076032A3 Alphavirus replicon packaging constructs |
| 03/01/2007 | WO2006075187A3 Animals exhibiting an altered preference for an addictive substance |
| 03/01/2007 | WO2006072845A3 Gram positive bacterial cells comprising a disrupted flagellin gene, flagellin-based fusion proteins and use in removal of metal ions from a liquid |
| 03/01/2007 | WO2006069220A3 Modified human growth hormone |
| 03/01/2007 | WO2006069200A3 Group b streptococcus |
| 03/01/2007 | WO2006031181A8 Methods for identifying a patient as a candidate for treatment with a long acting beta agonist and for predicting a patient’s response to long acting beta2 agonist therapy by analysing polymorphisms in the beta2-adrenergic receptor gene |
| 03/01/2007 | WO2005124341A3 Stable isotope labeled polypeptide standards for protein quantitation |
| 03/01/2007 | WO2005119255A3 Constrained cis-diol-borate bioconjugation system |
| 03/01/2007 | WO2005017107A3 Specific binding agents to hepatocyte growth factor |
| 03/01/2007 | WO2004096977A3 Crystal structure of homo sapiens adipocyte lipid binding protein and uses thereof |
| 03/01/2007 | WO2004084806A3 Protein modification and maintenance molecules |
| 03/01/2007 | WO2004081032A3 Novel litaf binding site peptides and methods of using the same |
| 03/01/2007 | WO2004045369A3 Nuclear receptor-based diagnostic, therapeutic, and screening methods |
| 03/01/2007 | WO2004011617A3 Identification of a novel bitter taste receptor, t2r76 |
| 03/01/2007 | WO2003086277A3 Attenuated gram negative bacteria |
| 03/01/2007 | US20070050869 Regulatory sequences useful for production of plants with modified embryo and/or endosperm development |